A groundbreaking trial conducted by the University of the Sunshine Coast (UniSC) has brought hope to individuals suffering from peripheral artery disease (PAD), a debilitating condition that affects blood flow to the legs. The study, funded by the UK-based Actegy, focused on a footplate muscle stimulation device, which has shown remarkable results in alleviating symptoms for patients with PAD.
PAD, a serious condition characterized by blocked arteries in the legs, can lead to severe complications such as pain, difficulty walking, gangrene, and even the need for amputation. It also poses a significant risk of heart attack or stroke. The UniSC FootPAD study aimed to explore an innovative approach to managing this challenging disease.
The trial involved assessing the 'Revitive Circulation Booster' device, which uses neuromuscular electrical stimulation to mimic the effects of exercise. While the initial six-minute walking test did not show an increase in total walking distance, the results were highly encouraging. Participants experienced significant improvements in pain-free walking and symptom relief.
Professor Christopher Askew, who led the study, emphasized the potential of this device as a complementary tool to traditional exercise therapy. He explained, "This device may act as a primer or stepping stone to exercise programs. By reducing symptoms, it could help patients engage more confidently in physical activity, which is ultimately the most effective long-term strategy."
The study's findings were presented at the American Heart Association's 2025 Scientific Sessions, a prestigious platform for groundbreaking research. Professor Askew highlighted the importance of this trial, stating, "This recognition reflects the strength of the data and the importance of testing therapies in real-world patient populations. It also underscores the value of academic-industry collaboration when conducted with scientific independence."
However, it is essential to note that the device is not a replacement for walking or traditional exercise programs. Instead, it serves as a supportive tool, particularly for patients who struggle with the initial stages of structured exercise due to pain and discomfort. The trial's results open up new possibilities for managing PAD and improving the quality of life for those affected by this vascular disease.
